{
    "nct_id": "NCT04637763",
    "official_title": "A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)",
    "inclusion_criteria": "* Age greater than or equal to 18 at the time of enrollment\n* Documented diagnosis of relapsed or refractory non-Hodgkin lymphoma after prior standard of care\n* Eastern Cooperative Oncology Group performance status 0 or 1\n* Adequate hematologic, renal, liver, cardiac and pulmonary organ function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior therapy with an anti-CD19 targeting agent\n* Active or chronic graft versus host disease requiring therapy\n* Prior allogeneic stem cell transplantation\n* Central nervous system (CNS) lymphoma, prior CNS malignancy\n* Prior seizure disorder, cerebrovascular ischemia, dementia, cerebellar disease or autoimmune disease with CNS involvement.\n* Primary immunodeficiency\n* Current or expected need for systemic corticosteroid therapy\n* Current thyroid disorder. Hypothyroidism controlled with stable hormone replacement is permitted\n* Other malignancy within 2 years of study entry, except curatively treated malignancies or malignancies with low risk of recurrence\n* Unwillingness to follow extended safety monitoring",
    "miscellaneous_criteria": ""
}